| HOME >> MEDICINE >> TECHNOLOGY |
10,922
20,548Deferred revenue
9,437
8,816Advanced subsidies
3,596
4,460Other taxes payable
4,699
2,790Convertible notes
35,864
--Other current liabilities
9,592
7,891 Total current liabilities94,019
59,568Non-current liabilities:Long-term debt, excluding current portion
1,791
1,852Advanced subsidies
3,338
2,934Convertible notes
--
35,864Other non-current liabilities
4,614
5,085 Total non-current liabilities9,743
45,735 Total liabilities103,762
105,303Equity:Ordinary shares ($0.02 par value, 5,002,550,000 authorized as of December 31, 2010 and March 31, 2011; 560,972,080 and 565,840,984 issued and outstanding as of December 31, 2010 and March 31, 2011, respectively)
11,317
11,219Additional paid-in capital
366,618
332,913Retained earnings
40,403
22,180Accumulated other comprehensive income
29,975
26,518 Total equity418,313
392,830 Total liabilities and equity522,075
498,133WUXI PHARMATECH (CAYMAN) INC.UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands of U.S. dollars, except ADS data and per ADS data) Three Months Ended March 31, 20112010% ChangeNet revenues:Laboratory Services
75,218
66,998
12%Manufacturing Services
18,337
13,604
35%Total net revenues93,555
80,602
16%Cost of revenues:Laboratory Services
(45,414)
(39,285)
16%Manufacturing Services
(13,447)
(10,899)
23%Total cost of revenues(58,861)
(50,184)
17%Gross profit:Laboratory Services
29,804
27,713
8%Manufacturing Services
4,890
2,705
81%Total gross profit34,694
30,418
14%Operating expenses:Selling and
'/>"/>
| SOURCE WuXi PharmaTech (Cayman) Inc Copyright©2010 PR Newswire. All rights reserved |